MedTrace Logo

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.

Conditions

Interventions

DRUG

GTx-758 1000mg

comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension

DRUG

Lupron Depot

comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension

DRUG

GTx-758 2000mg

comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension

Sponsors & Collaborators

  • GTx

    lead INDUSTRY

Principal Investigators

  • Mitchell Steiner, MD · GTx

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326312 on ClinicalTrials.gov